相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke
P. Amarenco et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Time Course of LDL Cholesterol Exposure and Cardiovascular Disease Event Risk
Michael J. Domanski et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease
Brian A. Ference et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants
Nelson Wang et al.
Lancet Diabetes & Endocrinology (2019)
Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study
Hiroshi Itoh et al.
DIABETES CARE (2018)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
G. G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Brian A. Ference et al.
EUROPEAN HEART JOURNAL (2017)
Cumulative in-trial and post-trial effects of blood pressure and lipid lowering: systematic review and meta-analysis
Yoichiro Hirakawa et al.
JOURNAL OF HYPERTENSION (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)
Michael A. Blazing et al.
AMERICAN HEART JOURNAL (2016)
Long-Term Effectiveness and Safety of Pravastatin in Patients With Coronary Heart Disease: Sixteen Years of Follow-Up of the LIPID Study
Wendy E. Hague et al.
CIRCULATION (2016)
Interpretation of the evidence for the efficacy and safety of statin therapy
Rory Collins et al.
LANCET (2016)
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
S. Yusuf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Next Steps in Primary Prevention of Coronary Heart Disease Rationale for and Design of the ECAD Trial
Michael J. Domanski et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mendelian Randomization Estimates May Be Inflated
C. Mary Schooling et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease A Mendelian Randomization Analysis
Brian A. Ference et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
Colin Baigent et al.
LANCET (2011)
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
Alessandro Liberati et al.
PLOS MEDICINE (2009)
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis
Anne B. Rossebo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Practical methods for incorporating summary time-to-event data into meta-analysis
Jayne F. Tierney et al.
TRIALS (2007)
Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial
Haruo Nakamura et al.
LANCET (2006)
High-dose atorvastatin vs usual dose simvastatin for secondary prevention after myocardial infarction - The IDEAL study: A randomized controlled trial
TR Pedersen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Intensive lipid lowering with atorvastatin in patients with stable coronary disease
JC LaRosa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
HM Colhoun et al.
LANCET (2004)
Effect of fluvastatin on cardiac outcomes in renal transplant recipients:: a multicentre, randomised, placebo-controlled trial
H Holdaas et al.
LANCET (2003)
Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care - The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT)
CD Furberg et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention - A randomized controlled trial
PWJC Serruys et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Quantifying heterogeneity in a meta-analysis
JPT Higgins et al.
STATISTICS IN MEDICINE (2002)
Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses
LL Kjaergard et al.
ANNALS OF INTERNAL MEDICINE (2001)
分享论文
